Site to site IP transfers are very rare for us and in accordance with EU regulations we only use them when patient safety or treatment continuity is at risk.

We are currently having a discussion of whether our quality group should ‘approve’ or ‘release’ the material before it can be used at the receiving site.

I am curious to hear if others quality group is involved in the process or if only the sending and receiving sites sign off on the acknowledgement of transfer form to attest it was received in good condition and within temperature range?